Mitsubishi UFJ Asset Management Co. Ltd. Purchases 68,122 Shares of Stryker Corporation $SYK

Mitsubishi UFJ Asset Management Co. Ltd. raised its position in Stryker Corporation (NYSE:SYK) by 8.7% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 847,430 shares of the medical technology company’s stock after buying an additional 68,122 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. owned 0.22% of Stryker worth $266,805,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently modified their holdings of the company. Sankala Group LLC bought a new position in shares of Stryker in the fourth quarter valued at approximately $26,000. Godfrey Financial Associates Inc. bought a new stake in Stryker during the fourth quarter worth $26,000. United Financial Planning Group LLC purchased a new position in Stryker in the third quarter worth $27,000. Atlas Capital Advisors Inc. purchased a new position in Stryker in the fourth quarter worth $27,000. Finally, DJE Kapital AG bought a new position in Stryker in the 4th quarter valued at $28,000. Institutional investors own 77.09% of the company’s stock.

Insider Transactions at Stryker

In other Stryker news, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the transaction, the vice president owned 10,582 shares in the company, valued at $3,247,298.34. This trade represents a 30.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of Stryker stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the completion of the transaction, the director owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. The trade was a 13.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 4.60% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on SYK. Deutsche Bank Aktiengesellschaft set a $315.00 target price on Stryker in a research report on Friday, May 1st. Citigroup reissued a “buy” rating on shares of Stryker in a report on Thursday. Weiss Ratings restated a “hold (c)” rating on shares of Stryker in a report on Friday, July 31st. Robert W. Baird set a $385.00 price objective on shares of Stryker in a research report on Friday, May 1st. Finally, BTIG Research lowered their price objective on shares of Stryker from $371.00 to $358.00 and set a “buy” rating on the stock in a research report on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $386.28.

Stryker Stock Performance

Shares of SYK opened at $331.75 on Tuesday. The firm has a market cap of $127.25 billion, a PE ratio of 34.38, a PEG ratio of 2.16 and a beta of 0.76. The stock’s fifty day moving average price is $325.21 and its two-hundred day moving average price is $333.24. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $396.86.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. The firm had revenue of $6.59 billion for the quarter, compared to analysts’ expectations of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The business’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, equities research analysts forecast that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a dividend of $0.88 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 annualized dividend and a yield of 1.1%. Stryker’s dividend payout ratio is 36.48%.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.